24769-56-0

tetranor-PGEM is the major urinary metabolite of PGE₁ and PGE₂, and is used as a marker of PGE₂ biosynthesis. About 15% of an infused dose of PGE₂ appears as this metabolite in the urine of humans. Normal healthy males excrete 7-40 μg of tetranor-PGEM over a 24-hour period.

The major urinary metabolite of Prostaglandin E2 (P838610).

ChEBI: A prostanoid that is prostaglandin E2 in which the acyclic hydroxy group has been oxidised to the corresponding ketone, the methyl group has been oxidised to the corresponding carboxylic acid and the 6-carboxyhexenyl group has been oxidatively cleaved to a 2-carboxyethyl group. It is the major urinary metabolite of prostaglandin E2.

[1] JASON R. NEALE  Brian J D. Liquid chromatography–tandem mass spectrometric quantification of the dehydration product of tetranor PGE-M, the major urinary metabolite of prostaglandin E2 in human urine[J]. Journal of Chromatography B, 2008, 871 1: Pages 72-77. DOI: 10.1016/j.jchromb.2008.06.042
[2] YOSHIFUMI MORITA. Simultaneous analyses of urinary eicosanoids and related mediators identified tetranor-prostaglandin E metabolite as a novel biomarker of diabetic nephropathy.[J]. Journal of Lipid Research, 2021: 100120. DOI: 10.1016/j.jlr.2021.100120
[3] YONG CUI. Urinary prostaglandin E2 metabolite and breast cancer risk.[J]. ACS Applied Electronic Materials, 2014: 2866-2873. DOI: 10.1158/1055-9965.epi-14-0685